Life After COVID: Long-Term Health, Brain, and Heart Risks

For most people who catch COVID-19, the acute illness resolves within a few weeks and normal life resumes. But for a significant minority, the infection leaves a lasting mark. Somewhere between roughly 7 and 35 percent of COVID survivors develop lingering symptoms that persist for months or longer, a condition now widely called long COVID. Beyond individual health, the pandemic reshaped work patterns, childhood education, mental health trends, and how scientists think about immune memory. Life after COVID, in other words, is not simply a return to the status quo.

How Common Long COVID Actually Is

Estimates of long COVID prevalence vary widely depending on how it is defined, how long after infection people are assessed, and which population is studied. A broad review of the literature places the range at 10 to 35 percent of all COVID survivors experiencing at least one persistent symptom, with fatigue, shortness of breath, chest pain, depression, anxiety, memory problems, and difficulty concentrating among the most frequently reported.¹ That wide range partly reflects how hard it is to separate symptoms caused by the virus from symptoms people would have had anyway.

A large nationwide study in Scotland tried to address this by comparing COVID survivors to matched controls who had never tested positive. After adjusting for confounders, the prevalence of symptoms directly attributable to the infection was about 7 percent at six and twelve months, rising to roughly 10 percent at eighteen months.² That adjusted figure is considerably lower than the crude numbers often cited in headlines, but it still means millions of people worldwide are affected. The study also found that women were more likely to have attributable symptoms, while people with more pre-existing health conditions actually had lower attributable prevalence, probably because their baseline symptom burden was already high enough to blur the difference.

Why Symptoms Persist

Researchers have converged on several overlapping mechanisms that explain why COVID hangs around in some people’s bodies long after the initial infection clears from the airways. One leading theory involves viral reservoirs: fragments of the virus, or even replicating virus, persist in tissues like the gut, lungs, brain, and lymph nodes for months to years. These reservoirs drive chronic inflammation and continuously stimulate immune cells, eventually wearing them out.³ The reservoir may also release viral proteins into the bloodstream, triggering clotting abnormalities and immune dysfunction far from the original site of infection.⁴

Another piece of the puzzle involves damage to blood vessels. COVID-19 inflames the endothelium, the thin layer of cells lining every blood vessel in the body. When that lining is chronically damaged, it sets the stage for microclots, impaired blood flow, and organ dysfunction that persists well beyond the acute phase.⁵ Recent work has shown that markers of neutrophil extracellular traps, sticky webs of DNA and enzymes released by immune cells, are elevated in people with long COVID and are structurally associated with the size and number of microclots circulating in their blood.⁶ In other words, the immune system’s own cleanup machinery may be stabilizing tiny blood clots that would normally dissolve, contributing to the fatigue, brain fog, and exercise intolerance that define so many long COVID cases.

What COVID Does to the Brain

Cognitive complaints, often summarized as “brain fog,” are among the most debilitating and frustrating long COVID symptoms. The underlying biology involves persistent inflammation inside the central nervous system. Immune cells called microglia remain activated long after infection, pumping out inflammatory signals that damage synapses and injure neurons. The blood-brain barrier, which normally keeps circulating immune molecules out of brain tissue, becomes leaky, allowing peripheral immune cells and inflammatory mediators to infiltrate the brain.⁷ This sustained neuroinflammation, driven by activated microglia and astrocytes along with disrupted cytokine signaling, promotes long-term brain dysfunction.⁸

Brain imaging studies are beginning to reveal structural changes. An MRI study comparing people with long COVID to those who recovered fully and to people never infected found altered tissue microstructure across all three groups, with the long COVID group showing the most pronounced differences. These alterations correlated with physical and cognitive function scores.⁹ Another study found that people with post-COVID condition had increased cortical thickness in certain frontal brain regions, and that this thickening was associated with worse working memory performance. White matter tracts connecting distant brain regions also showed signs of disruption.¹⁰

A nationwide MRI cohort study offered some reassurance on the structural side: most people with post-COVID condition had normal or near-normal white matter scores on standard scales, and the overall lesion burden did not differ significantly from controls after adjusting for age. Still, about 4 percent showed distinct lesions consistent with inflammation or demyelination at six months, and a small proportion had cranial nerve enhancement visible on contrast imaging.¹¹ The brain changes are real, but they are not uniform: many long COVID patients show subtle shifts detectable only with advanced imaging, while a smaller subset has more obvious abnormalities.

When Smell and Taste Do Not Come Back

Loss of smell was one of the signature symptoms of early COVID-19 waves. Most people recover their sense of smell within weeks, but a meaningful fraction experience prolonged olfactory dysfunction that can last months or years, sometimes accompanied by parosmia, where familiar smells become distorted and unpleasant. The virus does not primarily attack the smell-sensing neurons themselves. Instead, it targets supporting cells in the nasal lining called sustentacular cells, which express the receptor the virus uses to enter cells. When these support cells are damaged, the olfactory neurons lose their structural scaffolding. If the sustentacular cells recover quickly, the neurons survive and function returns. If recovery is slow, the neurons die, and the system must regenerate from stem cells, a process that slows with age.¹²

In people with persistent smell loss, biopsies have revealed ongoing inflammation and T-cell infiltration in the olfactory tissue, even when no detectable viral RNA remains. This chronic inflammatory state suppresses stem cell regeneration and may also cause olfactory receptors to be expressed at lower levels, which could explain the fluctuating nature of smell distortion that many patients describe. In effect, the immune response meant to clear the virus ends up sabotaging the tissue’s ability to heal itself.

Heart and Metabolic Risks After Infection

COVID-19 raises the risk of cardiovascular events well beyond the acute illness. A large study of over 150,000 patients found that people with long COVID had about 1.6 times the risk of new-onset cardiovascular disease of any type, including arrhythmias, heart failure, ischemic heart disease, and blood clots.¹³ A US Veterans Affairs cohort study of comparable size confirmed this, reporting about a 63 percent higher risk of any cardiovascular outcome in the year after infection compared to contemporary controls.¹⁴

There is an important time dimension. A UK matched-cohort study found that cardiovascular risk was dramatically elevated in the first four weeks after diagnosis, with pulmonary embolism, atrial arrhythmias, and venous clots showing the largest spikes. By five to twelve weeks, the excess risk had already dropped substantially. And in the period from thirteen to fifty-two weeks, there was no evidence of a net increase in cardiovascular events for most categories; for some, like pulmonary embolism and stroke, rates actually fell below expected levels.¹⁵ So while the cardiovascular danger is real, it is concentrated in the weeks immediately following infection and recedes for most people over time.

COVID also appears to increase the risk of developing diabetes. A systematic review and meta-analysis estimated that the relative risk of new diabetes after COVID-19 was about 1.6 times higher than in uninfected people, with the association holding across all adult age groups and even in children.¹⁶ Another review found that the risk for new-onset type 2 diabetes after infection ranged from about 1.3 to 2.7 times the baseline risk, with severity of illness, age, and smoking among the strongest predictors.¹⁷ A separate meta-analysis estimated the overall prevalence of new-onset diabetes among COVID patients at roughly 8 percent, dominated by type 2 diabetes.¹⁸ The mechanisms likely involve direct viral damage to insulin-producing cells in the pancreas, combined with the inflammation and metabolic stress of infection.

Immunity After COVID and Vaccination

Your immune memory of SARS-CoV-2 depends heavily on the combination of infections and vaccinations you have accumulated. So-called hybrid immunity, the combination of at least one infection and at least one vaccine dose, consistently outperforms either source of protection alone. A large Israeli study found that vaccinated individuals who had never been infected saw their protection wane rapidly: adjusted infection rates roughly quadrupled within six months of their second dose. Previously infected people who then received a single vaccine dose maintained much lower infection rates over the same period.¹⁹

A Czech study spanning the Omicron era ranked immunity sources from weakest to strongest: full vaccination alone was least durable, followed by booster vaccination, then prior infection, and finally hybrid immunity from a combination of boosting and infection. Against both BA.1/2 and BA.4/5 Omicron subvariants, hybrid immunity induced by booster vaccination provided the strongest and most stable protection, with about 97 to 99 percent effectiveness against severe disease still holding at five to six months.²⁰ Antibody studies in adults who received an adenovirus-based vaccine and then had a breakthrough infection showed that binding antibodies remained at levels associated with protection against symptomatic infection for at least a year.²¹

One complication is immune imprinting. Because most people’s first exposure to a SARS-CoV-2 spike protein was through the original Wuhan-strain vaccine, their immune system tends to preferentially recall memory cells trained against that original spike whenever it encounters a newer variant. Even after the updated XBB.1.5 monovalent booster, the antibody response was dominated by recall of pre-existing memory B cells rather than by fresh cells trained on the new variant. Neutralizing antibodies against JN.1, the lineage that gave rise to currently circulating strains, were about four-fold lower than against the vaccine-matched XBB.1.5 target.²² This does not mean boosters are useless; they still raise neutralizing titers against newer variants. But the immune system’s bias toward its first impression means that updated vaccines never quite perform as well against the newest variants as the original vaccine did against the original virus.

Children and Long COVID

Children get long COVID less often than adults, but it does happen. One estimate puts the rate at roughly 1 to 3 percent of children with recognized infections.²³ A prospective cohort study that followed over 1,200 pediatric patients found that about 24 percent reported persistent symptoms at three months, though this dropped sharply over time: roughly 12 percent remained symptomatic at six months, and only about 1 percent at eighteen months. Fatigue, exertional shortness of breath, and headache were the most common complaints. Older age, hospitalization during acute illness, and having pre-existing conditions all raised the risk of prolonged symptoms, while the Omicron variant was associated with lower risk compared with earlier strains.²⁴ The symptom profile in children includes respiratory, neuropsychiatric, and general complaints like muscle weakness.²⁵

Treating Long COVID

The honest state of long COVID treatment is frustrating: the evidence base remains thin and most interventions are supported by low to very low certainty data. A narrative review of candidate treatments identified only six interventions with randomized controlled trial evidence specific to long COVID. Exercise rehabilitation had the most data behind it (sixteen trials), followed by multicomponent rehabilitation packages and coenzyme Q10 supplements, each with a handful of trials. Antivirals, vagus nerve stimulation, and monoclonal antibodies each had only one small trial.²⁶

One well-designed trial specifically targeting cognitive symptoms tested computerized brain training, a structured cognitive rehabilitation program, and transcranial direct current stimulation, a form of gentle electrical brain stimulation. None of the three active interventions showed benefits on cognitive outcomes compared to the control group. Secondary measures, including participant-reported outcomes and formal neuropsychological testing, also showed no differential benefit for any treatment arm.²⁷ This does not mean brain fog is untreatable forever, but it underscores how early the field is. Many clinics offer symptom management, pacing strategies, and rehabilitation, which help patients function better even without addressing the root cause.

The Healthcare Burden

Long COVID places a measurable strain on healthcare systems. A large OpenSAFELY cohort study in the UK estimated that people with a long COVID diagnosis used about 49 percent more healthcare resources in the following year than a comparison group, visiting healthcare providers roughly 30 times per year versus 16 times for comparators. Healthcare costs were about 44 percent higher, amounting to roughly £2,500 per person per year compared to £1,500.²⁸ Among people who had been hospitalized before their long COVID diagnosis, there was a nearly three-fold increased risk of being hospitalized again compared to non-long-COVID patients.²⁹ Even in a smaller population-based Swiss cohort, about 40 percent of participants had contacted the healthcare system for COVID-related reasons, and a third of those who had not fully recovered reported no further healthcare contact at all, suggesting many people are suffering without professional support.³⁰

Who Bears the Burden Unequally

Long COVID does not affect all communities the same way. Research suggests that Black and Hispanic Americans are more likely to develop long COVID than white Americans, a disparity partly tied to differences in access to private health insurance, which appears to be a protective factor.³¹ Social determinants of health, including poverty, racism, and discrimination, strongly influence both COVID-19 outcomes and the trajectory of long-term recovery.³²

Paradoxically, who gets diagnosed with long COVID does not mirror who is most at risk of developing it. An analysis of diagnostic patterns found that the long COVID sample was disproportionately female, white, and privately insured compared to the broader pool of COVID-19 patients. Among Medicaid-insured patients, Black patients were underrepresented in long COVID diagnoses relative to their share of COVID cases, while white patients were overrepresented.³³ This gap between who develops long COVID and who gets diagnosed with it has real consequences: patients without a formal diagnosis have a harder time accessing specialized care, workplace accommodations, and disability support.

Youth Mental Health and the Learning Gap

The pandemic’s indirect effects on young people may prove as consequential as the virus itself. Globally, age-standardized disability from depressive and anxiety disorders increased by about 16 to 17 percent between 2010 and 2021, with the pandemic accelerating a trend already underway.³⁴ A repeated cross-sectional study of Finnish youth found that the proportion experiencing clinically significant anxiety and depression symptoms rose from pre-pandemic levels to 2021 and remained elevated through 2023. Girls in lower secondary education saw the steepest increases. One group that bucked the trend was transgender youth, among whom anxiety and depression rates actually fell between 2021 and 2023, potentially reflecting reduced exposure to in-person bullying during school closures, though the data cannot confirm a single explanation.³⁵

A nationwide study in another country offered a more reassuring picture for adults: overall, lockdowns did not severely alter pre-pandemic mental health trends. Suicide rates and psychiatric referrals were actually lower during the first lockdown, and most indicators returned to baseline afterward, though psychotropic medication use did increase during the pandemic compared to pre-pandemic trends.³⁶ The picture is not one of universal crisis, but rather of specific vulnerable groups, particularly adolescents and young women, bearing a disproportionate psychological burden.

School closures left a measurable academic deficit. An analysis of international math and science assessment data found that student performance dropped significantly below where long-term trends predicted it should be. The damage was greater for older students: eighth graders lost the equivalent of close to a full year of schooling in some subjects, while fourth graders lost roughly half a year. Longer closure durations predicted larger drops.³⁷ Early systematic reviews had already flagged evidence of learning loss in most studied populations, with certain demographic groups, particularly lower-income students, experiencing more severe setbacks than others.³⁸

How Work and Cities Reorganized

One of the pandemic’s most durable societal changes is the rise of remote and hybrid work. Using spending, commuting, migration, and housing data from multiple countries, researchers documented a persistent “donut effect”: economic activity dispersed away from city centers in cities with high levels of remote work. About three-fifths of households that left big-city centers in the United States moved to the suburbs of the same metropolitan area rather than to entirely different regions, a pattern consistent with hybrid arrangements where employees still commute to an office a few days a week. As of 2024, the donut effect shows no signs of reversing, suggesting that metropolitan areas will remain intact but with economic weight shifted outward from their cores.³⁹

Monitoring the Virus Going Forward

SARS-CoV-2 has not disappeared; it continues to circulate and evolve. One tool that gained prominence during the pandemic and is likely to remain important is wastewater surveillance. By measuring viral RNA concentrations in municipal sewage, public health authorities can track community-level transmission without relying solely on individual testing, which has dropped dramatically since the emergency phase. A study in Southwest Iran, for example, found a strong correlation between wastewater viral RNA levels and confirmed case counts in the region, demonstrating that wastewater monitoring can serve as an early-warning system, particularly in resource-limited settings where clinical testing capacity is low.⁴⁰ Trust in science continues to play a role in how people engage with public health measures: research shows that higher trust reduces belief in conspiracy theories and promotes more positive attitudes toward vaccination, both of which shape individual and community-level outcomes during ongoing waves.⁴¹

1
PubMed Central. Epidemiological and clinical perspectives of long COVID syndrome ↩︎
2
Nature Communications. True prevalence of long-COVID in a nationwide, population cohort study ↩︎
3
PubMed Central. Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID ↩︎
4
Nature Immunology. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC) ↩︎
5
PubMed Central. Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook ↩︎
6
PubMed Central. Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients ↩︎
7
PubMed Central. The Molecular Mechanisms of Cognitive Dysfunction in Long COVID: A Narrative Review ↩︎
8
Translational Psychiatry. Understanding neuroinflammation in post-COVID-19 syndrome: biological mechanisms, diagnostic biomarkers, and therapeutic prospects ↩︎
9
Brain, Behavior, & Immunity – Health. Altered brain tissue microstructure and neurochemical profiles in long COVID and recovered COVID-19 individuals: A multimodal MRI study ↩︎
10
Brain Communications. Structural brain changes in post-COVID condition and its relationship with cognitive impairment ↩︎
11
PubMed Central. Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study ↩︎
12
PubMed Central. Recovery rates and long‐term olfactory dysfunction following COVID‐19 infection ↩︎
13
European Journal of Preventive Cardiology. Cardiovascular disease as part of Long COVID: a systematic review ↩︎
14
Nature Medicine. Long-term cardiovascular outcomes of COVID-19 ↩︎
15
PLOS Medicine. Cardiometabolic outcomes up to 12 months after COVID-19 infection: A matched cohort study in the UK ↩︎
16
PubMed Central. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis ↩︎
17
PubMed Central. Diabetes Mellitus after SARS-CoV-2 Infection: An Epidemiological Review ↩︎
18
PubMed Central. Prevalence of new‐onset diabetes following COVID ‐19 infection: A systematic review and meta‐analysis ↩︎
19
PubMed Central. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 ↩︎
20
PubMed Central. Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants ↩︎
21
PubMed Central. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine ↩︎
22
Immunity. Persistence of immune imprinting after XBB.1.5 mRNA booster vaccination in humans ↩︎
23
PubMed Central. Diagnosis and management of post-COVID (Long COVID) in children: a moving target ↩︎
24
EClinicalMedicine. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study ↩︎
25
PubMed Central. Long COVID in children and adolescents: prevalence, clinical manifestations, and management strategies ↩︎
26
PubMed Central. Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities ↩︎
27
JAMA Neurology. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial ↩︎
28
PubMed Central. Healthcare utilisation in people with long COVID: an OpenSAFELY cohort study ↩︎
29
PubMed Central. Effects of long COVID on healthcare utilization ↩︎
30
PLoS ONE. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study ↩︎
31
PubMed Central. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19 ↩︎
32
PubMed Central. Long COVID and Health Inequities: The Role of Primary Care ↩︎
33
Preventive Medicine Reports. Exploring Long COVID diagnostic equity by sex, race and ethnicity, and insurance type ↩︎
34
PubMed Central. Post-pandemic mental health: Understanding the global psychological burden and charting future research priorities ↩︎
35
The Lancet Psychiatry. Youth mental health before, during, and after the COVID-19 pandemic in Finland ↩︎
36
Brain. Mental health disorders before, during and after the COVID-19 pandemic: a nationwide study ↩︎
37
Learning and Instruction. The learning crisis: Three years after COVID-19 ↩︎
38
PubMed Central. Learning loss during Covid-19: An early systematic review ↩︎
39
PubMed Central. How working from home reshapes cities ↩︎
40
PubMed Central. Integrating wastewater surveillance for future pandemic preparedness by tracking SARS-CoV-2 RNA in municipal wastewater in Southwest Iran ↩︎
41
PubMed Central. The Impact of Trust in Science on COVID-19 Vaccine Attitudes: Parallel Mediation Through Conspiracy Beliefs and General Vaccine Hesitancy ↩︎